Riana Therapeutics GmbH, a spin-off from Vetmeduni Vienna founded this year, has entered into a collaborative agreement with the Lead Discovery Center GmbH (LDC) to support its efforts to discover and develop novel cancer therapeutics that disrupt oncogenic protein-protein interactions (PPIs).

Senescence of lung epithelial tissue translates into fibrinolysis reduction and loss of tissue repair, both drivers of pulmonary fibrotic diseases. Researchers from Tokushima University reported on the effect of ARV-825, a BRD4 degrader, as an antifibrotic agent in lung fibrosis.

Additional early-stage research and drug discovery news in brief.

In accordance with the publishing schedule, BioWorld Science was not published on Monday, Sept. 11, 2023.

Additional early-stage research and drug discovery news in brief, from: Blue Earth, Sling.

Pivalent Therapeutics Inc. has reported the development of phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors.

ATP-dependent RNA helicase A (DHX9) inhibitors have been reported in an Accent Therapeutics Inc. patent as potentially useful for the treatment of cancer.

A Duke Street Bio Ltd. patent details new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.